Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

The conversation discusses skepticism about new hair loss treatments, with many users expressing doubt about their effectiveness compared to existing treatments like minoxidil and finasteride. Some users mention natural oils like olive and macadamia oil, but overall, there's a consensus that these are unlikely to be game changers.

A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The conversation humorously discusses diverting DHT from head to body hair and explores the idea of transplanting body hair to the scalp. It also mentions the potential for treatments to prevent DHT from affecting hair follicles.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.

Microneedling is preferred over laser therapy for hair loss because it is cheaper and reportedly effective, especially with minoxidil. Laser therapy is seen as costly and less effective.

Higher doses of dutasteride for hair loss are debated, with some users suggesting they are unnecessary and potentially unsafe. The original poster uses a combination of dutasteride, minoxidil, and RU58841 for hair regrowth, despite concerns about high dosages.

There is no consensus on how long to wait after dermarolling before applying Minoxidil, with some applying immediately and others waiting up to 24 hours. Users report varying experiences with side effects, and some also use finasteride or dutasteride in their hair loss treatment routines.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

A user tried various hair growth treatments, including drinking topical minoxidil, using oral minoxidil and finasteride, and applying GHK-Cu, growth hormone peptides, and liposomal sulforaphane. They experienced thicker hair, while others discussed the risks and benefits of these methods.

Microneedling may enhance hair loss treatment by increasing the effectiveness of topical minoxidil, especially for those lacking the necessary enzyme to activate it. It might also work by triggering growth factors and improving topical absorption.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

The user is currently using Minoxidil with melatonin, rosemary, peppermint, azelaic acid, and RU58841 for hair loss and plans to add fluridil and Pyrilutamide. They seek advice on the best Pyrilutamide source, noting Actifolic worked briefly.

Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.

The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.